Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016

CRANBURY, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics FOLD, a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software.  

A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on May 3, 2016. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 98970481.

About Amicus Therapeutics

Amicus Therapeutics FOLD is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other lysosomal storage disorders.

FOLD–G